XBIO Xenetic Biosciences, Inc.

Nasdaq xeneticbio.com


$ 2.70 $ 0.19 (7.57 %)    

Friday, 14-Nov-2025 12:33:12 EST
QQQ $ 611.53 $ 11.97 (2 %)
DIA $ 473.34 $ 1.91 (0.41 %)
SPY $ 674.40 $ 8.95 (1.34 %)
TLT $ 88.96 $ -0.83 (-0.92 %)
GLD $ 376.70 $ 3.81 (1.02 %)
$ 2.57
$ 2.53
$ 2.65 x 4,009
$ 2.71 x 100
$ 2.53 - $ 2.70
$ 2.20 - $ 13.93
44,610
na
5.89M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-18-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-22-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-29-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-30-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 xenetic-biosciences-q3-eps-033-beats-049-estimate-sales-1027m-beat-630000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $...

 micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.

 xenetic-biosciences-prices-offering-of-735k-common-shares-at-612shr-for-gross-proceeds-of-45m

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on ad...

 4-stocks-in-the-same-sector-just-made-a-huge-leap-in-momentum-rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam a...

 xenetic-biosciences-q2-eps-045-beats-065-estimate-sales-589897k-miss-720000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $...

 xenetic-biosciences-announces-first-patient-dosing-in-exploratory-clinical-study-of-systemic-dnase-i-in-combination-with-folfirinox-for-advanced-or-metastatic-pancreatic-cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, P...

 xenetic-biosciences-q1-eps-059-beats-072-estimate-sales-59326k-miss-67000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 xenetic-biosciences-q4-eps-068-misses-020-estimate-sales-64882k-beat-23000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION